top of page
A.S (10).png

Register today !

The 18th Annual Congress of Gynecologic Oncologists of Quebec, hosted by the RGOQ, eagerly extends an invitation to all professionals involved in the care of women facing or at risk of gynecological cancers; this includes gynecologic oncologists, hemato-oncologists, radiation oncologists, oncology nurses and research nurses.

This congress promises an opportunity to acquire fresh insights, engage in discussions with peers, and explore the latest advancements in prevention, treatment, and support strategies within this critical field.

Highlighted Topics Include:

  • A Warm Welcome from the President of the Regroupement

  • Trophoblastic Gestational Neoplasia: Exploring Recent Developments

  • Identifying Candidates for Cytology Screening in the Gynaecological Population

  • Safety Considerations for Simple Hysterectomy in Stage IB1 Cervical Cancer (FIGO 2018)

  • Exploring Novel Approaches to Rare Ovarian Tumors

  • Updates from Ovarian Cancer Canada: What's on the Horizon?

  • Venous Thromboembolism in Gynecologic Oncology: From Prevention to Treatment

  • Unpacking Immunomarkers in Gynaecological Neoplasia

  • The Role of IPO in Ovarian Cancer Maintenance Therapy

  • Staying Informed About the Latest Developments in Gynaecological NeoplasiaFellows' Perspective: Comprehensive Reviews of Endometrial Cancer, Cervical Cancer, and High-Grade Serous Ovarian Cancer

We look forward to your participation and hope you find inspiration and valuable insights from our carefully curated topics and esteemed guest speakers.

Desk with Stethoscope


18 November
Message from the President of the Regroupement
Dr. Alexandra Sebastianelli 
Gestational Trophoblastic Neoplasia (GTN): What's New?
Dr. Annick Pina and Dr. Geneviève Bouchard Fortier

Learning objectives:
  • Define the investigations required during the diagnosis of a GTN;
  • Describe the management of low-risk and high-risk GTNs;
  • Interpreting contemporary evidence on the role of immunotherapy in the treatment of GTN
  • Recognize the particularities in the management of ETTs and PSTTs;
  • Identify the place of a provincial, national and international network in practice.
8:40 Questions and answers

Identify individuals in the gynaecological population requiring cytology

Dr. Jean Grégoire

Learning objectives:

  • Defining the role of anoscopy in gynecology oncology;

  • Explain how a diagnostic anoscopic exam and treatment session will take place;

  • Discuss a horizon for the establishment of screening guidelines and a reference algorithm for cytology.

9:30 Questions and answers

Break | with the exhibitors
Is simple hysterectomy safe in patients with stage IB1 cervical cancer (FIGO 2018)
Dr. Marie Plante
Learning objectives:
  • Describe the basic concept of the SHAPE study.
  • Name the inclusion and exclusion criteria for the SHAPE study.
  • Integrate a rigorous assessment strategy into patient selection for less radical surgery.
10:50 Questions and answers
Novelties in rare ovarian tumors
Dr. Laurence Bernard and Dr. Léonie Dallaire-Nantel
Learning objectives:
  • Optimize the management of patients with rare ovarian disease, such as germ cells and low-grade serous carcinoma;

  • Identify scientific developments and treatment recommendations;

  • Discuss provincial standards of practice and identify opportunities for clinical studies.

11:40 Questions and answers
Updates from Ovarian Cancer Canada: What's on the Horizon?
12:20 Questions and answers
End of the morning
19 November
Venous thromboembolism in gynecologic oncology, from prevention to treatment
Dr. Marie-Pier Arseneault
Learning objectives:
  • Discuss the investigation and definitions of superficial and deep VTEs;
  • Review the evidence of VTE treatment modalities in patients with gynaecological cancer (DOAC, LMWH and VCI filter);
  • Describe best preventive practices for VTE in the gynecologic oncology population.
8:40 Questions and answers
Immunomarkers of gynaecological neoplasia
Dr. Chantale Morin
Learning objectives:
  • Describe the diagnostic approach to metastasis with associated immunomarkers.
  • Identify p53 marking patterns that are associated with BRCA mutation.
  • Determine the clinical contexts for which PDL1 analysis is required
  • Describe the methodology for the pathological analysis of cervical carcinomas.
9:30 Questions and answers
Break | with the exhibitors
The role of IPO in ovarian cancer maintenance therapy
Mme Anne-Marie Knight
Learning objectives:
  • Recognize the roles of the nurse navigator in the management of PARP inhibitors and the treatment with PARP inhibitors
  • Identify barriers to adherence to treatment with PARP inhibitors;
  • Discuss solutions to optimize adherence to treatment with PARP inhibitors.
10:30 Questions and answers
10:40 - 12:10
What's new in gynaecological neoplasia? Fellows' point of view
Learning objectives:
  • Summarize the results of the different prospective randomized controlled studies published
    during the last year;
  • Present the results of the various retrospective landmark studies published during the last year;
  • Provide an overview of current research protocols and upcoming studies.
Endometrial Cancer Review
Dr. Rayyan Rozzah

11:00 Questions and answers
Cervical Cancer Review
Dr. Maryam El Gani

11:30 Questions and answers
Review of high-grade serous ovarian cancer
Dr. Jessica Ruel Laliberté

12:00 Questions and answers
Closing remarks
End of the congress
This activity is an accredited group training activity (section 1) within the meaning given by the Maintenance of Certification (MDC) program of the Royal College of Physicians and Surgeons of Canada as well as a recognized professional development activity (category A) in the sense given to it by the College doctors from Quebec.

This activity has been approved by the Continuing Professional Development Department (DDPC) of the Federation of Specialist Physicians of Quebec. You can declare a maximum of 6.75 hours in section 1 / professional development activity recognized (category A). Participants must claim a number of hours consistent with the duration of their participation.


Our heartfelt gratitude for the generous support of our sponsors.

Platinum: GlaxoSmithKline (GSK), Gold: Merck Alliance and Merck-Eisai, Silver: Eisai, Bronze: AstraZeneca and Olympus.

The Venue


A unique hotel complex to be in the action and relax. Live the experience of the Hôtel du Domaine, located in Thetford, in Chaudière-Appalaches, less than 1h30 from the cities of Quebec, Sherbrooke and Drummondville.

$189-Price in single or double occupancy

·      A $20 fee applies per additional adult in hotel room.

·      Children 17 and under are accommodated free of charge.

·      Accommodation fees of $8 per night, lodging tax of 3.5%, GST and QST are extra.

·      Taxes are subject to change.

·      Check-in time: 16:00

·      Check-out time: 11:00 a.m


755 9e Rue S, Thetford Mines, QC G6G 0G1

​Room reservations before October 21:

By telephone: 1 844-321-5222
Group Code: AGQ1711
for more information contact

bottom of page